NCT01117571

Brief Summary

Study is prospective and multi-center. Study will include 100 to 200 patients across up to 20 sites.The study sites will be located in the United States.The study objective is to evaluate the safety and performance of the ConforMIS iUni® Unicompartmental Knee Resurfacing Device in patients with single compartment osteoarthritis.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2010

Longer than P75 for all trials

Geographic Reach
1 country

8 active sites

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2010

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

May 4, 2010

Completed
1 day until next milestone

First Posted

Study publicly available on registry

May 5, 2010

Completed
4.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2014

Completed
8.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 10, 2023

Completed
Last Updated

October 25, 2023

Status Verified

October 1, 2023

Enrollment Period

4.6 years

First QC Date

May 4, 2010

Last Update Submit

October 23, 2023

Conditions

Keywords

kneeosteoarthritisunicompartmentalarthroplastyknee resurfacingConformispatient specific

Outcome Measures

Primary Outcomes (2)

  • Knee Society Score

    to assess knee pain and function

    2 years

  • WOMAC Osteoarthritis Index

    to assess knee pain and function

    2 years

Secondary Outcomes (5)

  • Knee Society Score and WOMAC at years 5 and 10 post-implantation

    10 years

  • Annual revision rates at years 1 through 10 post-implantation

    10 years

  • Incidence of major procedure-related and device-related complications

    10 years

  • Length of tourniquet time in minutes

    6 weeks

  • Length of hospital stay in hours

    6 weeks

Study Arms (1)

open label

iUni® Unicompartmental Knee Resurfacing Device

Device: iUni® Unicompartmental Knee Resurfacing Device

Interventions

The iUni® Unicompartmental Resurfacing Device is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation

open label

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients over 18 who have uni-compartmental osteoarthritis to be treated with a unilateral knee resurfacing procedure

You may qualify if:

  • Clinical condition included in the approved Indications For Use
  • Unicompartmental osteoarthritis of the medial or lateral tibiofemoral compartment
  • Willingness to participate in the clinical study, to give informed consent and to attend all follow-up visits
  • \> 18 years of age

You may not qualify if:

  • Simultaneous bilateral procedure required
  • BMI \> 35
  • Treatment for cancer within the past 5 years, with the exception of skin cancer
  • Poorly controlled diabetes
  • Neuromuscular conditions which prevent patient from participating in study activities
  • Active local or systemic infection
  • Immunocompromised
  • Fibromyalgia or other general body pain related condition
  • Advanced tricompartmental osteoarthritis
  • Symptomatic patellofemoral disease
  • Rheumatoid arthritis or other forms of inflammatory joint disease
  • Loss of bone or musculature, osteoporosis, osteonecrosis, neuromuscular or vascular compromise in the area of the joint to be operated to an extent that the procedure is unjustified
  • Advanced loss of osteochondral structure on the affected femoral condyle
  • Compromised ACL, PCL or collateral ligament
  • Severe (\>15º) fixed valgus or varus deformity
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (8)

Arkansas Specialty Orthopaedics & HipKneeArkansas Foundation for the Facility

Little Rock, Arkansas, 72205, United States

Location

S.T.A.R. Orthopaedics

La Quinta, California, 92253, United States

Location

Center for the Knee and Shoulder

Monterey, California, 93940, United States

Location

JFK Medical Center

Atlantis, Florida, 33462, United States

Location

Heekin Clinic

Jacksonville, Florida, 32204, United States

Location

Great Lakes Bone and Joint

Battle Creek, Michigan, 49015, United States

Location

Orthopedic Associates of Pittsburgh

Monroeville, Pennsylvania, 15146, United States

Location

Advanced Orthopedics and Sports Medicine

Cypress, Texas, 77429, United States

Location

MeSH Terms

Conditions

Osteoarthritis

Condition Hierarchy (Ancestors)

ArthritisJoint DiseasesMusculoskeletal DiseasesRheumatic Diseases

Study Officials

  • C. Lowry Barnes, M.D

    Hip Knee Arkansas Foundation

    PRINCIPAL INVESTIGATOR
  • Marc Quartulli

    Restor3D

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 4, 2010

First Posted

May 5, 2010

Study Start

April 1, 2010

Primary Completion

October 30, 2014

Study Completion

January 10, 2023

Last Updated

October 25, 2023

Record last verified: 2023-10

Data Sharing

IPD Sharing
Will not share

Locations